Investing.com - Merck&Co (NYSE: MRK) reported third quarter EPS of $1.57, $0.07 better than the analyst estimate of $1.50. Revenue for the quarter came in at $16.66B versus the consensus estimate of $16.45B.
Guidance
Merck&Co sees FY 2024 EPS of $7.72-$7.77 versus the analyst consensus of $7.74.
Merck&Co sees FY 2024 revenue of $63.60B-$64.10B versus the analyst consensus of $64.15B.
Merck&Co's stock price closed at $104.83. It is down -9.00% in the last 3 months and up 1.93% in the last 12 months.
Merck&Co saw 0 positive EPS revisions and 16 negative EPS revisions in the last 90 days. See Merck&Co's stock price’s past reactions to earnings here.
According to InvestingPro, Merck&Co's Financial Health score is "great performance".
Check out Merck&Co's recent earnings performance, and Merck&Co's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar